Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s):  AWKNF

Healthcare Biotechnology
Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company... see more

Recent & Breaking News (CSE:AWKN)

Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions

Newsfile January 26, 2022

Awakn Life Sciences Signs MOU with Maps

Newsfile January 19, 2022

Awakn Responds to OTC Markets Request on Recent Promotional Activity

Newsfile January 14, 2022

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Newsfile January 11, 2022

Awakn Life Sciences Expands World's First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral Addictions

Newsfile January 5, 2022

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Newsfile January 4, 2022

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Newsfile December 15, 2021

Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors

Newsfile December 14, 2021

Awakn Life Sciences to Participate at Upcoming December Conferences

Newsfile December 3, 2021

Awakn Life Sciences Strengthens Executive Leadership Team

Newsfile November 30, 2021

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Newsfile November 16, 2021

Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of Psychiatry

Newsfile November 4, 2021

Awakn Life Sciences to Participate at the Wonderland: Miami Conference in November 2021

Newsfile November 2, 2021

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program

Newsfile October 28, 2021

Awakn Life Sciences to Present at the Benzinga Global Small Cap Conference

Newsfile October 22, 2021

Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval to Begin Treatments in the UK's First Medical Psychedelic Clinic

Newsfile October 20, 2021

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

PR Newswire October 11, 2021

Awakn Life Sciences to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th

Newsfile October 8, 2021

Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway

Newsfile October 5, 2021

NEO Bio Stock Acquires Exclusive Rights to MDMA Research from Imperial College London

Stockhouse Editorial September 23, 2021